Experimental pill for Hard-to-Treat blood cancers shows early promise
NCT ID NCT06761586
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This early-stage study tested an oral drug called AUR104 in 9 adults with relapsed or refractory lymphoid cancers (like certain lymphomas or leukemias). The main goal was to check the drug's safety and find the right dose. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SELECT RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Adwaita Cancer Hospital & ICU
Surat, Gujarat, 395009, India
-
Kiran Multi Super Speciality Hospital and Research Centre
Surat, Gujarat, 395004, India
-
Kolhapur Cancer Centre Pvt. Ltd.
Kolhāpur, Maharashtra, 416234, India
-
MMFHA Joshi Hospital
Pune, Maharashtra, 411004, India
-
Sunshine Global Hospitals
Surat, Gujarat, 395007, India
Conditions
Explore the condition pages connected to this study.